Quick Takeaways: Why It Matters? Lenivia strengthens Zoetis’ lead in monoclonal antibody–based pain management for dogs by adding a longer-acting OA option to its portfolio. Market-wise, a single injection providing up to three months of osteoarthritis pain...
Quick Takeaways Why It Matters? Gallant is on track to create one of the first mass‑market, disease‑modifying OA biologics in companion animals, shifting regenerative medicine from niche referral centers into everyday general practice via a simple, ready‑to‑use IV product. ...
